Latest Content

In a small, placebo-controlled trial, oral semaglutide reduced heavy drinking days and craving in adults with AUD, though it missed its primary end point.

The FDA's push for faster, more diverse trials misses the real fix: experts say AI simulation and readability, not red tape, close the gap.

HIV disrupts several steps required for durable antibody production; for example, CD4+ helper T cells are depleted and functionally impaired.

Acoramidis attenuated declines in patient-reported health status through 30 months, complementing previously reported survival and hospitalization benefits.

The meta-analysis of 17 studies found that frailty was strongly associated with cognitive impairment in CKD, highlighting the need for further research to determine a causal relationship.

This discussion will appear in the August issue of Evidence-Based Oncology.

Panel experts at Nashville’s IVBM event discussed matching cancer therapy intensity to disease, easing access barriers, and reforming pharmacy/PBM policies.

Oral zasocitinib delivered skin clearance once limited to injectable biologics in phase 3 psoriasis trials, including hard-to-treat sites.

A July AJMC study found metastatic cancer diagnoses significantly increase Medicaid spending, highlighting the potential budget benefits of earlier detection.